Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug ...

The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK‐M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in ...

Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their primary endpoints last year. The FDA has set a goal date of Sept. 7th ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

PYRUKYND received FDA approval for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in February 2022. The drug generated product revenue of $26.8 million for the ...

State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, PR China State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School ...

This month's cover highlights the article Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis by Tobias Ackermann, Saverio Tardito and colleagues. The ...